A Shared Neoantigen Vaccine Plus Immune Checkpoint Blockade Is Well-Tolerated

Major Finding: A shared neoantigen vaccine plus immune checkpoint blockade was well-tolerated in advanced solid tumors. Concept: Preliminary clinical activity was observed along with a hierarchy of neoantigen immunodominance. Impact: These results could improve future tumor antigen vaccine design to enhance immunogenicity and clinical outcomes.